CLINICAL TRIALS PROFILE FOR FLUDROCORTISONE ACETATE

All Clinical Trials for fludrocortisone acetate

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00118482 ↗	Clinical Trial for the Prevention of Vasovagal Syncope	Completed	Canadian Institutes of Health Research (CIHR)	Phase 4	2005-05-01	The main question in the study is whether people taking fludrocortisone are less likely to faint than people taking an inactive pill called a placebo. Fludrocortisone is a drug that stimulates the body to retain salt and water. The investigators know from some studies that it might prevent people from fainting at home and in the community, while they are carrying on with their lives. There is some evidence that salt and water retention help prevent fainting, but no one has a clear idea about whether this is true. This study will try to determine if that is true.
NCT00118482 ↗	Clinical Trial for the Prevention of Vasovagal Syncope	Completed	University of Calgary	Phase 4	2005-05-01	The main question in the study is whether people taking fludrocortisone are less likely to faint than people taking an inactive pill called a placebo. Fludrocortisone is a drug that stimulates the body to retain salt and water. The investigators know from some studies that it might prevent people from fainting at home and in the community, while they are carrying on with their lives. There is some evidence that salt and water retention help prevent fainting, but no one has a clear idea about whether this is true. This study will try to determine if that is true.
NCT01495910 ↗	A Study Examining Doses of Abiraterone Acetate in Adult Women With 21-Hydroxylase Deficiency	Completed	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 1	2011-12-01	The purpose of this study is to determine the minimum dose of abiraterone acetate needed to decrease serum androstenedione to age-appropriate levels in premenopausal women on steroid replacement for classic 21-hydroxylase deficiency.
NCT02017197 ↗	Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil	Completed	Fundação de Amparo à Pesquisa do Estado de São Paulo	Phase 4	2014-08-01	The purpose of this study is to assess whether the switch from branded to generic warfarin or between different generic warfarin tablets may cause fluctuation in the results of coagulation tests (International Normalized Rate, acronym INR) in patients, thus predisposing them to unnecessary risks.
NCT02017197 ↗	Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil	Completed	Federal University of São Paulo	Phase 4	2014-08-01	The purpose of this study is to assess whether the switch from branded to generic warfarin or between different generic warfarin tablets may cause fluctuation in the results of coagulation tests (International Normalized Rate, acronym INR) in patients, thus predisposing them to unnecessary risks.
NCT02574910 ↗	Androgen Reduction in Congenital Adrenal Hyperplasia, Phase 1	Active, not recruiting	Children's Hospital Los Angeles	Phase 1	2017-08-01	Children with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency tend to have elevated circulating levels of androgens, which can accelerate skeletal maturation and adversely impact adult height. Additionally, these children require supraphysiologic doses of hydrocortisone to suppress secretion of adrenal androgen precursors, and this treatment can retard linear growth. This study seeks to use oral abiraterone acetate (Zytiga)as an adjunct to approved CAH therapy (oral hydrocortisone and fludrocortisone) for pre-pubescent children with classic 21-hydroxylase deficiency in order to reduce daily requirement of hydrocortisone. In this Phase 1 study, the investigators will determine the minimum effective dose of abiraterone acetate that normalizes androstenedione levels during the 7-day Treatment Period.
NCT02574910 ↗	Androgen Reduction in Congenital Adrenal Hyperplasia, Phase 1	Active, not recruiting	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 1	2017-08-01	Children with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency tend to have elevated circulating levels of androgens, which can accelerate skeletal maturation and adversely impact adult height. Additionally, these children require supraphysiologic doses of hydrocortisone to suppress secretion of adrenal androgen precursors, and this treatment can retard linear growth. This study seeks to use oral abiraterone acetate (Zytiga)as an adjunct to approved CAH therapy (oral hydrocortisone and fludrocortisone) for pre-pubescent children with classic 21-hydroxylase deficiency in order to reduce daily requirement of hydrocortisone. In this Phase 1 study, the investigators will determine the minimum effective dose of abiraterone acetate that normalizes androstenedione levels during the 7-day Treatment Period.

Clinical Trial Conditions for fludrocortisone acetate

Condition Name

Condition Name for fludrocortisone acetate
Intervention	Trials
Prostatic Neoplasms	4
Healthy Participants	2
Metastatic Castration-Resistant Prostate Cancer	2
Congenital Adrenal Hyperplasia	2

Condition MeSH

Condition MeSH for fludrocortisone acetate
Intervention	Trials
Prostatic Neoplasms	6
Adrenogenital Syndrome	3
Adrenal Hyperplasia, Congenital	3
Hyperplasia	2

Clinical Trial Locations for fludrocortisone acetate

Trials by Country

Trials by Country for fludrocortisone acetate
Location	Trials
United States	56
China	27
United Kingdom	17
Japan	14
Australia	13

Trials by US State

Trials by US State for fludrocortisone acetate
Location	Trials
Texas	6
Maryland	5
California	5
Michigan	4
Virginia	4

Clinical Trial Progress for fludrocortisone acetate

Clinical Trial Phase

Clinical Trial Phase for fludrocortisone acetate
Clinical Trial Phase	Trials
PHASE1	6
Phase 4	2
Phase 3	2

Clinical Trial Status

Clinical Trial Status for fludrocortisone acetate
Clinical Trial Phase	Trials
Recruiting	7
COMPLETED	5
Active, not recruiting	2

Clinical Trial Sponsors for fludrocortisone acetate

Sponsor Name

Sponsor Name for fludrocortisone acetate
Sponsor	Trials
Merck Sharp & Dohme LLC	9
Orion Corporation, Orion Pharma	5
Children's Hospital Los Angeles	2

Sponsor Type

Sponsor Type for fludrocortisone acetate
Sponsor	Trials
Industry	16
Other	13
NIH	2

Last updated: May 23, 2026

Fludrocortisone Acetate clinical trials update, market analysis and forecast: status, pipelines, and commercialization outlook

Fludrocortisone acetate is an established, off-patent mineralocorticoid used for adrenal insufficiency and related disorders. No active, late-stage registration-driving trials or modern “new drug application” pipelines for fludrocortisone acetate are identifiable from publicly indexed trial registries within the information provided. Market activity is therefore driven by ongoing supply, label maintenance, generics, and formulation/brand competition rather than clinical-trial-led growth.

---

What is fludrocortisone acetate used for and which indications drive demand?

Key FDA-approved clinical uses

Fludrocortisone acetate is prescribed for:

• Primary adrenal insufficiency (congenital, idiopathic, autoimmune etiologies) as chronic mineralocorticoid replacement
• Secondary adrenal insufficiency management as clinically indicated with glucocorticoid therapy
• Salt-losing congenital adrenal hyperplasia (CAH) (with glucocorticoids) in standard care settings
• Orthostatic hypotension / neurogenic orthostatic hypotension in practice under guideline-based or off-label use depending on jurisdiction and prescriber pattern

Demand sensitivity

Demand tracks:

• Patient incidence of adrenal insufficiency and CAH,
• Steadiness of long-term replacement therapy adherence,
• Formularies and payor preferences for lowest-cost supply,
• Intermittent supply constraints that can shift market shares without changing total treated populations.

---

What clinical trials exist for fludrocortisone acetate and are any late-stage programs active?

Clinical trials landscape

Fludrocortisone acetate is generally treated as an established active pharmaceutical ingredient (API). For an updated clinical trials picture that is useful for investment or licensing decisions, the key signal is whether trials are:

• Phase 3 and/or registration-enabling,
• Focused on new formulations (extended-release, altered delivery, improved bioavailability),
• Exploring new patient populations or new endpoints that would change label scope.

Update status

No sufficient, publicly indexed evidence is provided here to assert the existence of any active late-stage (Phase 3) fludrocortisone acetate program, nor to enumerate specific trial identifiers, sponsors, enrollment timelines, or primary endpoints. As a result, the clinical trials “update” for fludrocortisone acetate is best characterized as:

• Replacement of aging product lots, regulatory maintenance, and generic/biosimilar-style competition dynamics rather than novel clinical development.

---

What patents protect fludrocortisone acetate and how does patent status affect commercialization?

Patent reality check

Fludrocortisone acetate is a long-established steroid. The commercial market is dominated by:

• Generics
• Authorized generics (where applicable)
• Multiple branded/legacy products depending on geography and manufacturer history

Exclusivity drivers

In mature generics markets, pricing and volume are more often influenced by:

• Orange Book listings (where specific products are tracked)
• Market withdrawal or reformulation
• Cyclic supply and manufacturing capacity
• Pharmacovigilance and label maintenance

Actionable implication

Patent estate protection for fludrocortisone acetate itself is typically not a barrier to broad entry. Instead, manufacturing and regulatory compliance define the constraint set.

---

What is the Orange Book status of fludrocortisone acetate products?

Orange Book dependency

Orange Book status is product-specific. For fludrocortisone acetate, business relevance lies in:

• Which products are listed as reference or market holders,
• Whether any non-expired patents cover:
  • Formulations (tablet composition),
  • Manufacturing processes,
  • Method-of-use claims.

Update status

No Orange Book listing data (application numbers, patent numbers, expiration dates, exclusivity codes) is included in the information provided. Therefore, a precise Orange Book status map cannot be produced here without risking inaccuracy.

---

What generic entry risks exist for fludrocortisone acetate tablets and what manufacturing/IP barriers matter?

Generic entry dynamics

In mature steroid APIs, “generic entry risk” is usually controlled by:

• Availability of validated polymorph and quality specifications
• Stability of formulation with consistent dissolution profile
• GMP compliance and inspection outcomes
• Ability to source API consistently (DMF and supplier qualification where relevant)

Key risk categories

• Bioequivalence risk: formulation-dependent dissolution and permeability characteristics
• Quality risk: impurity profile control and stability data set requirements
• Supply risk: capacity and batch-release throughput at manufacturers
• Regulatory risk: labeling updates and post-marketing requirements

Net effect

For most markets, these risks do not prevent entry at scale; they affect:

• timing of launches,
• pricing power,
• and the probability of short-term shortages.

---

How does fludrocortisone acetate compare with alternative mineralocorticoids (demand substitution)?

Substitution threats

The practical substitution set for mineralocorticoid replacement includes:

• Alternative mineralocorticoids used in some regions or clinical pathways,
• Off-label use patterns that may shift with guideline updates.

Business relevance

Because fludrocortisone acetate is widely used as standard replacement, substitution generally occurs only when:

• a payer restricts specific products,
• a supply interruption triggers temporary switches,
• clinicians shift to an alternative due to tolerability, monitoring convenience, or local availability.

Commercial implication

Switching is usually incremental, not a step-function demand loss.

---

How large is the fludrocortisone acetate market and what are the drivers of volume growth?

Market characterization

Fludrocortisone acetate is a chronic therapy. That typically implies:

• steady base demand,
• limited “indication expansion” effects without new label approvals,
• volume changes tied to:
  • population prevalence,
  • diagnostic coding trends,
  • pediatric CAH management patterns,
  • and adherence dynamics.

Projection framework (what you can model)

A credible market projection for a mature replacement therapy generally uses:

• Prevalence-based demand: estimated patients with primary adrenal insufficiency and salt-wasting CAH
• Dose distribution: average daily dose and prescribed strength mix
• Persistence curves: long-term refill behavior
• Switching and share: generics penetration vs legacy brand retention
• Price erosion: generic competition and wholesaler contracting cycles

Forecast update status

No quantitative sales base, patient estimates, or pricing data is included in the information provided. A numeric forecast cannot be generated without injecting unverifiable numbers.

---

What will most likely determine fludrocortisone acetate revenue in the next 3 to 5 years?

1) Generic share and contracting

Mature markets reward lowest landed cost. Revenue shifts will align with:

• procurement contracts,
• competitor pricing,
• and supply stability.

2) Manufacturing reliability

Steroid supply is sensitive to:

• batch consistency,
• quality investigations,
• and regulatory action history.

3) Label maintenance and safety updates

Post-marketing requirements can tighten labeling and monitoring language, affecting:

• clinician prescribing preferences,
• and payor coverage rules.

4) Glucocorticoid co-therapy patterns

Mineralocorticoid use depends on the overall adrenal replacement regimen. Shifts in glucocorticoid prescribing can influence fludrocortisone dosing intensity.

---

What clinical endpoints matter for new trials of fludrocortisone acetate products, if they appear?

If a new program emerges (most likely as formulation optimization), the registration-relevant endpoints usually include:

• Pharmacokinetics: Cmax, Tmax, AUC
• Mineralocorticoid effect surrogates: blood pressure, sodium/potassium balance
• Safety: edema, hypertension, hypokalemia, metabolic effects
• Patient acceptability: tablet size, dosing frequency adherence

---

Key Takeaways

• Fludrocortisone acetate is an established mineralocorticoid with demand primarily driven by chronic replacement therapy for adrenal insufficiency and salt-wasting CAH rather than novel late-stage clinical development.
• No sufficient public trial and Orange Book/patent listing data is provided here to enumerate an actionable “clinical trials update” with sponsors, phases, endpoints, or timelines, or to produce a precise patent/exclusivity map.
• Near-term commercial outcomes are expected to be driven by generics market structure, supply reliability, and contracting dynamics, not by trial-led label expansion.

---

FAQs

1) Are there any Phase 3 trials of fludrocortisone acetate registered on ClinicalTrials.gov?

No verified, phase-specific registry details are included in the provided information, so a definitive Phase 3 inventory cannot be stated.

2) Does fludrocortisone acetate have pediatric-specific clinical development requirements?

Pediatric use is part of standard CAH management. Specific trial requirements depend on product labeling and region-specific regulatory frameworks; no pediatric trial inventory is provided here.

3) What strengths and dosage forms dominate fludrocortisone acetate prescribing?

Market mix depends on locally supplied strengths and historical product availability; no product strength distribution data is included here.

4) What are the most common safety monitoring parameters with fludrocortisone acetate therapy?

Clinically typical monitoring includes blood pressure, electrolytes (sodium/potassium), and signs of fluid retention; exact monitoring requirements vary by label and clinical guideline.

5) How quickly can a generic fludrocortisone acetate enter the market once approved?

In mature APIs, launch timing depends on product readiness, distribution contracting, and supply capacity rather than clinical development; no approval-to-launch timing statistics are provided here.

---

References

1. ClinicalTrials.gov. (n.d.). Search results for fludrocortisone acetate. https://clinicaltrials.gov/
2. U.S. FDA. (n.d.). Drugs@FDA and Orange Book resources for fludrocortisone acetate products. https://www.accessdata.fda.gov/scripts/cder/daf/